89Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: Implications for future cancer therapy

Nanomedicine

Volumn 9, Issue 13, 2014, Pages 1923-1937

  Karmani, Linda ^a   Bouchat, Virginie ^b   Bouzin, Caroline ^a   Levêque, Philippe ^a   Labar, Daniel ^a   Bol, Anne ^a   Deumer, Gladys ^c   Marega, Riccardo ^d   Bonifazi, Davide ^d   Haufroid, Vincent ^c   Michiels, Carine ^b   Grégoire, Vincent ^a   Feron, Olivier ^a   Lucas, Stéphane ^b   Vander Borght, Thierry ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

^c Louvain Centre for Toxicology and Applied Pharmacology   (Belgium)

^d UNIVERSITY OF NAMUR   (Belgium)

Author keywords

89Zr; anti endoglin antibody targeted gold nanoparticles; biodistribution; cancer; CD105; immuno PET; molecular imaging

Indexed keywords

ANTIBODY CONJUGATE; ENDOGLIN; ENDOGLIN ANTIBODY; ENDOGLIN ANTIBODY GOLD NANOPARTICLE ZR 89; ENDOGLIN ANTIBODY GOLD NANOPARTICLE ZR 89 PLASMA POLYMERIZED ALLYLAMINE; GOLD NANOPARTICLE; MONOCLONAL ANTIBODY; NANOCONJUGATE; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; ANTIIDIOTYPIC ANTIBODY; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; GOLD; LEUKOCYTE ANTIGEN; METAL NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; IN VIVO STUDY; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MOLECULAR IMAGING; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY; RADIOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; GOLD; HUMANS; METAL NANOPARTICLES; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84908281139     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.185     Document Type: Article

References (62)

1. Julien DC, Behnke S, Wang G, Murdoch GK, Hill RA. Utilization of monoclonal antibody-Targeted nanomaterials in the treatment of cancer. MAbs 3(5), 467-478 (2011).
2. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: Recent advances and perspectives. Chem. Soc. Rev. 41(6), 2256-2282 (2012).
3. Mallidi S, Larson T, Aaron J, Sokolov K, Emelianov S. Molecular specific optoacoustic imaging with plasmonic nanoparticles. Opt. Express. 15(11), 6583-6588 (2007).
4. Glaser ES, Massey KL, Zhu C, Curley SA. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery 148(2), 319-324 (2010).
5. Tiwari PM, Vig K, Dennis VA, Singh R. Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1, 31-63 (2011).
6. Haruta Y, Seon BK. Distinct human leukemia-Associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc. Natl Acad. Sci. USA 83(20), 7898-7902 (1986).
7. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM. A new 180-kDa dermal endothelial cell activation antigen: In vitro and in situ characteristics. J. Invest. Dermatol. 100(1), 27-34 (1993).
8. Burrows FJ, Derbyshire EJ, Tazzari PL et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin. Cancer Res. 1(12), 1623-1634 (1995).
9. Miller DW, Graulich W, Karges B et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer. 81(4), 568-572 (1999).
10. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc. Res. 86(1), 12-19 (2010).
11. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer. 54(3), 363-370 (1993).
12. Clasper S, Royston D, Baban D et al. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 68(18), 7293-7303 (2008).
13. Yoshitomi H, Kobayashi S, Ohtsuka M et al. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 37(3), 275-281 (2008).
14. Hussein MR. Transforming growth factor-beta and malignant melanoma: Molecular mechanisms. J. Cutan. Pathol. 32(6), 389-395 (2005).
15. Sun T, Sun BC, Ni CS et al. Pilot study on the interaction between B16 melanoma cell-line and bone-marrow derived mesenchymal stem cells. Cancer Lett. 263(1), 35-43 (2008).
16. Letamendía A, Lastres P, Almendro N et al. Endoglin, a component of the TGF-beta receptor system, is a differentiation marker of human choriocarcinoma cells. Int. J. Cancer 76(4), 541-546 (1998).
17. Kumar S, Ghellal A, Li C et al. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 59(4), 856-861 (1999).
18. Romani AA, Borghetti AF, Del Rio P, Sianesi M, Soliani P. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J. Surg. Oncol. 93(6), 446-455 (2006).
19. Marioni G, D'Alessandro E, Giacomelli L, Staffieri A. CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J. Oral Pathol. Med. 39(5), 361-367 (2010).
20. Tanaka F, Otake Y, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin. Cancer Res. 7(11), 3410-3415 (2001).
21. Li C, Gardy R, Seon BK et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br. J. Cancer 88(9), 1424-1431 (2003).
22. Charpin C, Dales JP, Garcia S et al. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin. Cancer Res. 10(17), 5815-5819 (2004).
23. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011).
24. Mitchell DC, Bryan BA. Anti-Angiogenic therapy: Adapting strategies to overcome resistant tumors. J. Cell. Biochem. 111(3), 543-553 (2010).
25. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J. Clin. Oncol. 23(6), 1295-1311 (2005).
26. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with anti-human endoglin immunotoxin. Clin. Cancer Res. 3(7), 1031-1044 (1997).
27. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. 5(2), 371-382 (1999).
28. Tabata M, Kondo M, Haruta Y, Seon BK. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int. J. Cancer 82(5), 737-742 (1999).
29. Takahashi N, Haba A. Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61(21), 846-854 (2001).
30. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-Angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites. Int. J. Oncol. 29(5), 1087-1094 (2006).
31. Tsujie M, Tsujie T, Toi H et al. Anti-Tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int. J. Cancer 122(10), 2266-2273 (2008).
32. Uneda S, Toi H, Tsujie T et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int. J. Cancer 125(6), 1446-1453 (2009).
33. Marega R, Karmani L, Flamant L et al. Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: An in vivo and in vitro study. J. Mater. Chem. 22(39), 21305-21312 (2012).
34. Karmani L, Labar D, Valembois V et al. Antibody-functionalized nanoparticles for imaging cancer: Influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol. Imaging 8(5), 402-408 (2013).
35. Vugts DJ, van Dongen GAMS. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discov. Today Technol. 8(2-4), e53-e61 (2011).
36. van Dongen GAMS, Visser GWM, Lub-de-Hooge MN, De Vries EG, Perk LR. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 12(12), 1379-1389 (2007).
37. Holland JP, Sheh YC, Lewis JS. Standardized methods for the production of high specific-Activity zirconium-89. Nucl. Med. Biol. 36(7), 729-739 (2009).
38. Kandil SA, Scholten B, Saleh ZA, Youssef AM, Qaim SM, Coenen HH. A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of 88Zr and 89Zr in proton induced reactions on yttrium. J. Radioanal. Nucl. Chem. 274(1), 45-52 (2007).
39. Vosjan MJWD, Perk LR, Visser GW et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Prot. 5(4), 739-743 (2010).
40. Perk LR, Vosjan MJWD, Visser GW et al. p-Isothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 37(2), 250-259 (2010).
41. Moreau N, Michiels C, Masereel B et al. PVD synthesis and transfer into water-based solutions of functionalized gold nanoparticles. Plasma Process Polymer. 6(1), S888-S892 (2009).
42. Masereel B, Dinguizli M, Bouzin C et al. Antibody immobilization on gold nanoparticles coated layer-by-layer with polyelectrolytes. J. Nanopart. Res. 13(4), 1573-1580 (2011).
43. Hong H, Yang Y, Zhang Y et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur. J. Nucl. Med. Mol. Imaging. 38(7), 1335-1343 (2011).
44. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur. J. Nucl. Med. Mol. Imaging 34(4), 532-540 (2007).
45. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: What we have learned so far?. J. Nanopart. Res. 12(7), 2313-2333 (2010).
46. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: Some physiological principles. Occup. Med. (Lond.) 56(5), 307-311 (2006).
47. Hirota K, Hasegawa T, Hinata H et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release 119(1), 69-76 (2007).
48. Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 10(8), 607-613 (2002).
49. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
50. Mahmoud M, Borthwick GM, Hislop AA, Arthur HM. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: Implications for two familial vascular dysplasias, HHT and PAH. Lab. Invest. 89(1), 15-25 (2009).
51. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29(12), 1912-1919 (2008).
52. Tinianow JN, Gill HS, Ogasawara A et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl. Med. Biol. 37(3), 289-297 (2010).
53. Mealey J Jr. Turn-over of carrier-free zirconium-89 in man. Nature 179(4561), 673-674 (1957).
54. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl. Med. Biol. 38(5), 675-681 (2011).
55. Glazer ES, Curley SA. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer 116(13), 3285-3293 (2010).
56. Moran CH, Wainerdi SM, Cherukuri TK et al. Size-dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields. Nano Res. 2(5), 400-405 (2009).
57. Chang MY, Shiau AL, Chen YH, Chang CJ, Chen HH, Wu CL. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci. 99(7), 1479-1484 (2008).
58. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49(18), N309-N315 (2004).
59. Raoof M, Curley SA. Non-invasive radiofrequency-induced targeted hyperthermia for the treatment of hepatocellular carcinoma. Int. J. Hepatol. 676957 (2011).
60. Rosen LS, Hurwitz HI, Wong MK et al. A Phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin. Cancer Res. 18(17), 4820-4829 (2012).
61. Fonsatti E, Del Vecchio L, Altomonte M et al. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J. Cell. Physiol. 188(1), 1-7 (2001).
62. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54(3), 363-370 (1993).